Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab

Background: The aim of this study was to compare the extent of pathologic response in patients with HER2-positive (HER2+) breast cancer treated with standard neoadjuvant chemotherapy, with or without trastuzumab (H), according to hormone receptor (HR) status. Patients and methods: We included 199 pa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Peintinger, F., Buzdar, A. U., Kuerer, H. M., Mejia, J. A., Hatzis, C., Gonzalez-Angulo, A. M., Pusztai, L., Esteva, F. J., Dawood, S. S., Green, M. C., Hortobagyi, G. N., Symmans, W. F.
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2008
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2733116/
https://ncbi.nlm.nih.gov/pubmed/18667396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdn427
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares